Meeting
2023 ASCO Annual Meeting
A subset of neutrophils as a predictive biomarker for immunotherapy response in patients with non–small-cell lung cancer and melanoma.
Authors
Yuval Shaked
Technion, Haifa, Israel
Yuval Shaked , Madeleine Benguigui , Ruth Halaban , Antonella Bacchiocchi , Iris Kamer , Jair Bar , Michal Lotem , Shai Shen-Orr , Mario Sznol , Tim J Cooper
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Circulating Biomarkers
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2557)
DOI
10.1200/JCO.2023.41.16_suppl.2557
Abstract #
2557
Poster Bd #
399
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Plasma-derived cfDNA to reveal potential biomarkers of response prediction and monitoring in non-small cell lung cancer (NSCLC) patients on immunotherapy.
First Author: Francesco Vallania
Poster
2020 ASCO Virtual Scientific Program
Novel blood-based biomarker predicting severe toxicity in melanoma anti-CTLA-4 immunotherapy treatment.
First Author: Vylyny Chat
Poster
2018 ASCO Annual Meeting
Serum interleukin 8 (IL-8) may serve as a biomarker of response to immuno-oncology (I-O) therapy.
First Author: Michael Carleton
Poster
2024 ASCO Annual Meeting
A phase I/II study to evaluate the safety, pharmacokinetics, and efficacy of PRJ1-3024 in patients with advanced solid tumors.
First Author: Panpan Zhang